Figure 5. Human pancreatic ductal adenocarcinomas with SWI/SNF aberrations exhibit responsiveness to platinum-based treatment regimens and increased DNA copy number transitions.

(A, B) Pancreatic cancer cases with SWI/SNF aberrations are associated with improved overall survival in patients receiving (B) platinum-based therapy, but not (A) gemcitabine alone. Kaplan-Meier curves with log-rank P-values shown. (C) Pancreatic cancers with SWI/SNF aberrations harbor significantly more DNA copy number transitions (segments). Scatter plots show mean with SD, along with Mann-Whitney P-values. (D–F) Same analyses as above, but omitting samples flagged by the Expert Pathology Committee (EPC) (see comments in main text).